Moderna (MRNA) Return on Invested Capital (2020 - 2026)

Moderna (MRNA) has 7 years of Return on Invested Capital data on file, last reported at 0.16% in Q1 2026.

• On a quarterly basis, Return on Invested Capital fell 14.0% year-over-year to 0.16% in Q1 2026; TTM through Mar 2026 was 0.16%, a 14.0% decrease from a year earlier, with the FY2025 full-year figure at 0.59%, down 46.0% from the prior year.
• Return on Invested Capital for Q1 2026 stood at 0.16%, down from 0.13% in the prior quarter.
• Over the last five years, Return on Invested Capital for MRNA reached as high as 0.07% in Q1 2022 and fell as low as 0.16% in Q1 2026.
• Historically, Return on Invested Capital has averaged 0.02% across 5 years, with a median of 0.01% in 2023.
• Across the five-year window, Return on Invested Capital gained 5 bps in 2022 and decreased 14 bps in 2026, its largest moves.
• Year by year, Return on Invested Capital stood at 0.02% in 2022, then slumped by 163 bps to 0.01% in 2023, then decreased by 29 bps to 0.02% in 2024, then plunged by 635 bps to 0.13% in 2025, then slipped by 20 bps to 0.16% in 2026.
• Per Business Quant data, the three most recent Return on Invested Capital figures were 0.16% in Q1 2026, 0.13% in Q4 2025, and 0.06% in Q3 2025.